论文部分内容阅读
为探讨β-葡糖苷酸酶(β-glucuronidase,β-GUase)蛋白量可否作为肝病患者肝细胞坏死的指标,作者对166例经肝活检、血管造影或手术证实的各种肝病,应用酶联免疫吸附法(ELISA)测定血清β-GUase 蛋白量,其中包括肝癌(HCC)32例,肝硬化(LC)43例,慢性活动性肝炎(CAH)54例,慢性持续性肝炎(CPH)22例,急性肝炎(AH)7例,肝非特异性变化(NSR)8例。53名外周血及生化检查无异常者作为对照组。结果①HCC、LC、CAH 患者血清β-GU-ase 蛋白量均显著高于对照组(Γ<0.01),而 CPH
To explore whether β-glucuronidase (β-glucuronidase) protein can be used as an index of liver cell necrosis in liver disease, we used enzyme linked immunosorbent assay (ELISA) for 166 liver biopsy, angiography or surgically proven liver diseases. Serum β-GUase protein levels were determined by ELISA, including 32 cases of hepatocellular carcinoma (HCC), 43 cases of liver cirrhosis (LC), 54 cases of chronic active hepatitis (CAH) and 22 cases of chronic persistent hepatitis (CPH) , 7 cases of acute hepatitis (AH) and 8 cases of non-specific liver changes (NSR). 53 cases of peripheral blood and biochemical tests without abnormal as a control group. Results ① The serum levels of β-GU-ase in patients with HCC, LC and CAH were significantly higher than those in the control group (Γ <0.01), while CPH